



Figure 4 – supplement 2. Loss of *Ptf1a* promotes pancreatic epithelial transdifferentiation and proliferation. (A-C) Immunofluorescence for CK19 (red), the Cre reporter Rosa26^{EYFP} (green), and CD45 (white) in *Ptf1a* cKO pancreata, 2 weeks after high-dose TM administration. Caerulein-treated *Ptf1a* cKO pancreas included as control for pancreatitis (B). Enlarged boxed area highlights EYFP+ acinar cells expressing CK19, surrounded by CD45+ leukocytes. (D-E) Immunofluorescence for E-cadherin (green), cleaved Caspase-3 (red) and DAPI (blue) in control and *Ptf1a* cKO pancreata. (F) Pancreatic lymph node, positive control for cleaved Caspase-3 staining. (G-H) Immunofluorescence for E-cadherin (green), Ki67 (red) and DAPI (blue). (I) Quantification of Ki67+/E-cadherin+ cells per 40x field (n=3 per group, $P < 0.05$). Scale bars: (A-F) 100 μ m, (G-H) 50 μ m.